The inhibition of VDR by its antagonist blocks PD-L1 expression, reduces the tumor burden in nude mice, and promotes anti-tumor immunity in acute myeloid leukemia, ovarian cancer, and pancreatic cancer [194]. Here, CD274 is linked to neoplasm.